The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.
申请人:THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as
represented by THE SECRETARY, DEPARTMENT OF HEALTH
AND HUMAN SERVICES
公开号:EP1633749A2
公开(公告)日:2006-03-15
US7498336B2
申请人:——
公开号:US7498336B2
公开(公告)日:2009-03-03
[EN] DEAZAFLAVIN COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSES DE DEAZAFLAVINE ET LEURS METHODES D'UTILISATION
申请人:US HEALTH
公开号:WO2004073615A2
公开(公告)日:2004-09-02
The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.
Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils
作者:George E. Wright、Neal C. Brown
DOI:10.1021/jm00175a007
日期:1980.1
irreversibly binding to the enzyme. Several 6-(alkylamino)uracils were weak inhibitors of DNA polymerases III; the optimum alkyl groups for enzyme binding were n-pentyl and n-hexyl, which apparently can occupy the planar enzyme binding site. The varied activities of 6-anilinouracils on a mutant DNA polymerase, resistant to 6-(phenylhydrazino)- and 6-(benzylamino)uracils bearing a p-OH or NH2 group, have altered